The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm

Vincent Marmouset , Magalie Joris (1) , Lavinia Merlusca , Marie Beaumont (2) , Amandine Charbonnier (3) , Jean-Pierre Marolleau (4, 5) , Berengere Gruson (1)

1 CHU Amiens-Picardie
2 Laboratoire d'Hématologie [CHU Amiens]
3 LCE - Laboratoire Chrono-environnement (UMR 6249)
4 Service clinique des Maladies du Sang
5 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666

We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemotherapy, we observed two complete responses and one clinical remission. Together with the encouraging literature data on the effects of lenalidomide and bortezomib on BPDCN cells, our results might prompt further investigations of this regimen's value in BPDCN.

Domaines: Sciences du Vivant [q-bio]

Vincent Marmouset, Magalie Joris, Lavinia Merlusca, Marie Beaumont, Amandine Charbonnier, et al.. The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematological Oncology, 2019, 37 (4), pp.487-489. ⟨10.1002/hon.2671⟩. ⟨hal-03605014⟩